What's happening with PuriflOH's sterilization trial plans?
In June last year PO3 announced it was intending to trial its Bluemist surface sterilization system in a “clinical laboratory environment” at Monash University’s DID/Department of Infectious Diseases.
Then, in his November Presentation, PO3 Detroit-based ED, Steve Annear, ran a time line showing that the Monash sterilization trial would start in Q1/2019.
PO3 chairman, Steve Morris, had the option to deliver a trial planning update in has AGM address on November 30, in his Market Activities Update on January 21 and in his Half Yearly Report on February 28.
But Morris had nothing to say about the Monash trial. His silence indicates it won’t be happening.
Why not? Is it because of cost; administration issues; flaws in the Bluemist system and/or flaws in the way Monash’s DID runs trials?
Perhaps it’s none of the above. Perhaps the key reason is that Monash is based in Melbourne and PuriflOH is now based in Detroit.
Observers say that PuriflOH will still run a trial of its FRG technology for surface sterilization but the trialling will occur in Michigan.
Decisions on location of the trial(s) and trial protocols are expected to be made - if they haven’t already been made - by Jim Heath, the man now in charge of commercializing PO3’s FRG system for medical room sterilization and medical instrument sterilization.
“Stryker Hero” Heath, former President of Stryker Instruments, would be familiar with Michigan laboratories – as would billionaire PO3 director Bill Parfet, principal of Upjohn Laboratories (now PO3’s second ranking shareholder) and former director of global medical instruments player, Stryker Corporation.
Neither Heath nor Parfet were involved with PuriflOH went it started Bluemist trial talks with Monash.
Now they’re playing key roles in PuriflOH, they can be expected to address another critical issue to commercialization. This relates to the Federal Drugs Administration.
At the AGM, PO3 Melbourne-based ED, Simon Lill, confirmed that the FRG sterilization tech would need to be cleared by the FDA.
Now, with hands-on input from Heath and Parfet, it should be much easier for PuriflOH to prepare compelling FDA dossier material in Detroit than it would be in Melbourne.
PO3 Price at posting:
$3.80 Sentiment: Hold Disclosure: Held
(20min delay)
